Doyle Mittie has filed 13 insider transactions across 2 companies since July 2024.
Most recent transaction: a option exercise of 679 shares of Avalo Therapeutics, Inc. ($AVTX) on April 01, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 679 | $8.04 | 4,301.0000 | 18,133,968 | 18.75% | 0.00% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 679 | $0.00 | 148,329.0000 | 18,133,968 | 0.46% | 0.00% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 679 | $16.00 | 3,622.0000 | 18,133,968 | 15.79% | 0.00% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | S | Common Stock | 25492 | $16.15 | 3,622.0000 | 18,133,968 | 87.56% | 0.14% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 19500 | $0.00 | 214,500.0000 | 18,133,968 | 8.33% | 0.11% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Stock Option (Right to Buy) | 5992 | $0.00 | 149,008.0000 | 18,133,968 | 3.87% | 0.03% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 19500 | $12.65 | 23,122.0000 | 18,133,968 | 538.38% | 0.11% |
| March 16, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | M | Common Stock | 5992 | $8.04 | 29,114.0000 | 18,133,968 | 25.91% | 0.03% |
| Feb. 26, 2026 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 105000 | $0.00 | 105,000.0000 | 18,133,968 | 9999.99% | 0.58% |
| Dec. 10, 2025 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | F | Common Stock | 1013 | $4.10 | 3,622.0000 | 18,133,968 | 21.86% | 0.01% |
| Aug. 7, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Doyle Mittie | Not found | A | Stock Option (Right to Buy) | 79456 | $0.00 | 79,456.0000 | 58,510,610 | 9999.99% | 0.14% |
| Jan. 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 155000 | $0.00 | 155,000.0000 | 0 | 9999.99% | 0.00% |
| July 15, 2024 | Avalo Therapeutics, Inc. | $AVTX | Doyle Mittie | Chief Medical Officer | A | Stock Option (Right to Buy) | 234000 | $0.00 | 234,000.0000 | 0 | 9999.99% | 0.00% |